Ibrutinib | BTK inhibitor
NMR (Conforms)
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 10 mg | $40.00 | ||
| 50 mg | $125.00 |
Ibrutinib (936563-96-1) is a very potent (IC50 = 0.5nM) irreversible inhibitor of Bruton tyrosine kinase (BTK) that blocks activation of the B-cell antigen receptor (BCR).1 Ibrutinib also potently inhibits several other kinases including BLK, BMS, FGR, EGFR, and ITK. It is a clinically useful drug to treat B cell cancers. It inhibits CLL cell migration and survival2,3 and downregulates expression of CD204. It enhanced antitumor immune responses in combination with anti PD-L1 blockade via its inhibition of ITK (IL2-inducible T-cell kinase).5
References/Citations:
1) Honigberg et al. (2010), The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy; Proc. Natl. Acad. Sci. USA 107 13075
2) Ponader et al. (2012), The Bruton tyrosine kinase Inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo; Blood 119 1182
3) De Rooij et al. (2012), The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia; Blood 119 2590
4) Pavlasoca et al. (2016), Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis; Blood 128 1609
5) Sagiv-Barfi et al. (2015), Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK; Proc. Natl. Acad. Sci. USA 112 E966
6) Weber et al. (2017), Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity, Front. Immunol. 8 1454
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Ibrutinib (936563-96-1) is a very potent (IC50 = 0.5nM) irreversible inhibitor of Bruton tyrosine kinase (BTK) that blocks activation of the B-cell antigen receptor (BCR).1 Ibrutinib also potently inhibits several other kinases including BLK, BMS, FGR, EGFR, and ITK. It is a clinically useful drug to treat B cell cancers. It inhibits CLL cell migration and survival2,3 and downregulates expression of CD204. It enhanced antitumor immune responses in combination with anti PD-L1 blockade via its inhibition of ITK (IL2-inducible T-cell kinase).5
References/Citations:
1) Honigberg et al. (2010), The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy; Proc. Natl. Acad. Sci. USA 107 13075
2) Ponader et al. (2012), The Bruton tyrosine kinase Inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo; Blood 119 1182
3) De Rooij et al. (2012), The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia; Blood 119 2590
4) Pavlasoca et al. (2016), Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis; Blood 128 1609
5) Sagiv-Barfi et al. (2015), Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK; Proc. Natl. Acad. Sci. USA 112 E966
6) Weber et al. (2017), Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity, Front. Immunol. 8 1454
Related products
-
Tigecycline | Antibiotic
From $50.00CAS:220620-09-7Catalog Number:10-3900Activity:AntibioticChemical Name:(4S,4aS,5aR,12aR)-9-[[2-(tert-Butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamideAlternate Names:9-t-Butylglycylamidominocycline; GAR-936Molecular Weight:585.66Molecular Formula:C29H39N5O8Solubility:Soluble in DMSO (up to at least 25 mg/ml).Physical Properties:Orange solidPurity:98% by HPLC
NMR (Conforms)Storage Temperature:-20°Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.Shipping Code:RT -
iCRT5 | Beta-catenin inhibitor
From $57.00CAS:18623-44-4Catalog Number:10-1371Activity:Beta-catenin inhibitorChemical Name:4-[5-(3,4-Dimethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-butyric acidMolecular Weight:367.44Molecular Formula:C16H17NO5S2Solubility:Soluble in DMSO (up to 30 mg/ml)Physical Properties:Yellow solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.Shipping Code:RT -
Rucaparib phosphate | PARP1 inhibitor
From $70.00CAS:459868-92-9Catalog Number:10-3321Activity:PARP1 inhibitorChemical Name:8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-oneAlternate Name:AG-14699; PF01367338Molecular Weight:421.36Molecular Formula:C19H18FN3O • H3PO4Solubility:Soluble in DMSO (up to 25 mg/ml).Physical Properties:Yellow solidPurity:98% by HPLC
NMR (Conforms)Storage Temperature:-20°Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
